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Abstract
Sepsis-induced myocardial dysfunction has traditionally been
thought of as principally affecting systolic heart function. One of
the primary reasons for this concept is that systolic dysfunction
is relatively easy to conceptualize, visualize, and measure. With
the advent of preload-independent measurements for diastolic
function, both measurement and conceptual difficulties are
being resolved, and a new realm of evidence is beginning to
emerge regarding the aberrations that are found during cardiac
relaxation in sepsis. A recent article in Critical Care brings this
issue into sharper focus.
In the previous issue of Critical Care, Joulin and colleagues [1]
describe an animal model of lipopolysaccharide (LPS)-
induced impaired myocardial systolic and diastolic function.
Diastole is composed of two physiological phenomena: myo-
cardial stiffness, which is energy independent, and active
relaxation, which is an ATP-requiring process [2]. Current
echocardiographic techniques can help distinguish which of
the two is the predominant pathway, although these tech-
niques may not always be practical in critically ill patients [3].
In some patients with sepsis, a reversible component to
impaired ventricular relaxation has been demonstrated [4],
which would imply that the energy-requiring component of
diastolic function is more perturbed in certain patients. One
might wonder why this is an important distinction to make, but
considering that increased mortality in sepsis may be corre-
lated with increasing fluid administration [5], it would seem
that being able to distinguish between isolated systolic,
diastolic, or combined dysfunction may prove to be life saving.
In addition, therapeutic measures might reasonably be aimed
at active relaxation.
Isolated and reversible left ventricular diastolic dysfunction
was recently demonstrated in septic patients [4]. This was
achieved by serial transesophageal echocardiographic meas-
urement of standard indices of systolic function, as well as
analyzing diastolic mitral inflow and annular tissue Doppler
patterns, the current standard in echocardiographic grading of
diastolic function [4]. This study highlighted the fact that we
should be cognizant that not all patients suffering from sepsis
and shock should be treated uniformly, and that choices of
intravenous resuscitation and vasopressor therapies need
careful consideration. The study further elucidated the revers-
ible nature of the impaired ventricular relaxation in humans,
suggesting that a metabolic or molecular process may be
responsible.
Considerable work has been done on defining the molecular
biology of diastole. An attractive mechanism currently thought
to play a major role is that of calcium flux. Systole is initiated by
rapid elevation of myocyte intracellular calcium, both through
influx (through L-type calcium channels) and calcium-mediated
calcium release from the sarcoplasmic reticulum (through the
ryanodine receptor) [6]. Calcium itself then initiates conforma-
tional changes in the contractile apparatus that mediates con-
traction. Re-uptake of calcium into the sarcoplasmic reticulum
by sarcoplasmic reticulum Ca2+-ATPase (SERCA) allows for
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cardiac relaxation. The ability of SERCA to pump calcium back
into the sarcoplasmic reticulum is governed by phospholam-
ban, a sarcoplasmic reticulum membrane-bound modulatory
protein [7]. The rapidity at which calcium is returned to the sar-
coplasmic reticulum is directly related to the rapidity of cardiac
relaxation. In the unphosphorylated state, phospholamban
inhibits calcium uptake by SERCA, and subsequently slows
diastole. Signaling by protein kinase leads to phosphorylation
of phospholamban, which, in turn, diminishes its inhibitory
activity on SERCA, promoting cardiac relaxation. In a knockout
mouse model lacking phospholamban, SERCA activity is unin-
hibited, and diastolic dysfunction with aging is not seen [8].
While other pathways, such as sodium-calcium exchange, are
important in myocardial calcium trafficking, those are currently
beyond the scope of this comment, and will not be described.
Joulin and colleagues, in their experiments, were able to dem-
onstrate a SERCA-dependent aberration in diastolic cardio-
myocyte behavior. In particular, in their experiments, they were
able to demonstrate a SERCA-dependent aberration in diasto-
lic cardiomyocyte behavior. The force-frequency relationship
(that is, heart-rate-dependent increase in cardiomyocyte short-
ening) and frequency-dependent acceleration of relaxation are
physiological phenomena that ensure maintenance of cardiac
output with the decreased ejection and filling times that are
consequences of higher heart rates. The group hypothesized
that LPS would disrupt this delicate balance by exerting an
effect on the molecular workings within the cardiomyocyte –
principally through the inhibition of the phosphorylation of
phospholamban. By utilizing echocardiographic measure-
ments of diastole, and through western blot analyses, they
were able to demonstrate a correlation between LPS-induced
myocardial relaxation dysfunction (frequency-dependent
acceleration of relaxation depression) and SERCA function.
It is important to note that this work was done in a murine
model of LPS infusion, a model with potentially important dif-
ferences from septic patients being treated in the intensive
care unit [9]. It is well known that the mediators of the sepsis
syndrome are numerous. Anesthetic agents were used to reg-
ulate heart rates, and real-time alterations in physiological
functioning may have been missed. The group studied only the
sarcoplasmic reticulum when calcium trafficking is also linked
to mitochondrial function and integrity, nitric oxide production,
the beta-adrenergic response, and potential protective effects
on the myocardium during prolonged sepsis [10].
Would specific targeting of intracellular calcium, or SERCA-
related protein kinase and phosphatase result in better hemo-
dynamics in septic shock? There is already a body of evidence
to suggest that calcium-sensitizing agents, such as levosi-
mendan, may improve hemodynamics in sepsis. In two animal
models, left ventricular relaxation was improved after treatment
with levosimendan in contrast to inotropes, such as milrinone
or dobutamine [11,12], and in a clinical trial, levosimendan
proved useful in improving global hemodynamic measure-
ments [13]. The study by Joulin and colleagues is certainly
thought provoking, and will hopefully lead us closer to devel-
oping better strategies for dealing with sepsis-induced myo-
cardial dysfunction – both its systolic and diastolic
components.
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